Biotech/Pharmaceuticals
"There has been some evidence that Zelapar ... has an even lower risk than selegiline, though this data may not have been enough to satisfy the FDA," a BioMedTracker report says. Sagient doesn't own shares or have a financial relationship with companies it evaluates.
At best, Zelapar could reach the market in a few months, Sagient says. "In the worst-case scenario, an additional [clinical] trial could be required to support efficacy or safety, which could take years," the firm says. Zelapar belongs to a class of drugs called selective irreversible monoamine oxidase type B inhibitors, or MAO-B inhibitors. MAO-B is an enzyme that breaks down dopamine, a chemical produced in the brain to help maintain balance and movement. When dopamine-producing cells die, people develop tremors and other neurological impairments. MAO-B inhibitor drugs try to thwart the damage caused by MAO-B enzymes, but their impact usually doesn't last very long. Zelapar is the second MAO-B inhibitor to recently receive a conditional approval notice from the FDA. Two months ago, Teva Pharmaceutical Industries (TEVA) got conditional clearance for Agilect. Teva wouldn't discuss details. At the time, the company said "there remain a number of issues that Teva believed it had resolved with its submissions, but as to which the FDA continues to have concerns." Sagient Research speculates that the government agency may have raised food-related concerns about the Teva drug, too.TheStreet Premium Services
Jim Cramer's Action Alerts PLUS:
Trade right alongside a Wall Street pro — enjoy access to his Charitable Trust portfolio and be sent trade alerts BEFORE he makes a move. Learn MoreOptionsProfits:
Get 50+ trade ideas a week from the industry's top options experts. Plus — exclusive commentary on market trends and essential trading tools. Learn MoreReal Money:
Our team of professional Wall Street Pros — including Jim Cramer, Doug Kass, and Nicholas Vardy — delivers intelligent analysis, timely trade ideas, and colorful commentary. Learn MoreStocks Under $10:
Break into the market with small- and mid-cap stocks... all $10 or less! David Peltier tells you exactly which low-priced stocks he's buying and selling. Learn MoreTo begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
blog comments powered by Disqus
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note |
|
|---|---|---|---|---|
| 12,438.67 | 1,311.48 | 2,828.01 | 15.81 |
Oil *
102.03
|
|
UP
18.81 |
DOWN
1.84 |
DOWN
9.35 |
DOWN
0.44 |
10 Yr
1.58%
SPDR Gold
151.62
|
|
+0.15%
|
-0.14%
|
-0.33%
|
-2.71%
|
Data delayed 20 minutes |


Connect with TheStreet